Role of adjuvant endocrine therapy in early-stage breast cancer
HB Muss - Seminars in oncology, 2001 - Elsevier
The value of adjuvant endocrine therapy in saving lives of women with estrogen receptor-
positive (ER+) early-stage breast cancer cannot be disputed. Tamoxifen has proven to be
effective in improving relapse-free and overall survival in both pre-and postmenopausal
women with ER+ early-stage breast cancer. In the meta-analysis of the Early Breast Cancer
Trialists' Collaborative Group, the proportional reduction in recurrence and mortality for 5
years of tamoxifen therapy was 50% and 28% respectively for patients with ER+ tumors …
positive (ER+) early-stage breast cancer cannot be disputed. Tamoxifen has proven to be
effective in improving relapse-free and overall survival in both pre-and postmenopausal
women with ER+ early-stage breast cancer. In the meta-analysis of the Early Breast Cancer
Trialists' Collaborative Group, the proportional reduction in recurrence and mortality for 5
years of tamoxifen therapy was 50% and 28% respectively for patients with ER+ tumors …
